Octreotide for bowel obstruction

Data set includes

• individual participant data for 112 consenting participants
• CSV files for the number of days free of vomiting as reported by patients daily, measured 72 hours after the first administration of study medication
• patient-rated Global Impression of Change
• the number of patient-reported episodes of vomiting
• survival as date of death
• nausea and Pain scores using NCI CTCAE criteria and Brief Pain Inventory
• functional status (Australian modified Karnofsky Performance Scale (AKPS)
• protocol defined “as needed” symptom control medications (hyoscine butylbromide for colicky pain, morphine for pain, haloperidol for nausea)
• quality of life measures used the EORTC C15, Facit Pal
• caregiver quality of life was measured using the Caregiver Quality of Life Index
• data is available for screening, baseline, each day of intervention, and four weeks of follow up
• health service utilisation data was collected for up to 4 weeks post intervention.

Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey

Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction

Octreotide for Malignant Bowel Obstruction: Commentary on Currow et al